医学
阶段(地层学)
回顾性队列研究
肺炎
放化疗
内科学
不利影响
临床终点
化疗
放射治疗
外科
疾病
癌症
多中心研究
多元分析
免疫疗法
肺癌
临床试验
肿瘤科
肺炎
危险系数
生存分析
性能状态
比例危险模型
总体生存率
作者
Mingjun Xu,Yan Xu,Yingchun Man,Xuqin Xiang,Dexin Jia,Junzhu Dai,Weitong Gao,Ruqiong Wang,Bo An,Kaile Zhao,Jiaojiao Li,Bo Pan,Yan Yu
摘要
Concurrent or sequential chemoradiotherapy followed by immunotherapy (CCRT/SCRT→IO), known as the PACIFIC regimen, is the standard of care for unresectable, driver gene-negative Stage III non-small cell lung cancer (NSCLC). However, in real-world practice, some patients cannot proceed to immunotherapy due to toxicity, declining performance status, or disease progression. This multicenter retrospective study included 960 patients from 14 Chinese institutions (2011-2023) to evaluate the efficacy and safety of alternative regimens. Patients were stratified into five groups. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints included objective response rate, disease control rate, duration of response, and immune-related adverse events (irAEs). Inverse probability treatment weighting was used to adjust for baseline differences. Among 911 evaluable patients, weighted median PFS was 21.7 months for (IO + CCRT/SCRT) → IO, 16.8 for (IO + Chemo) → IO, 25.8 for CCRT/SCRT → IO, 7.1 for chemotherapy alone, and 14.8 for CCRT/SCRT. Median OS was not reached in the (IO + CCRT/SCRT) → IO group and ranged from 31.1 to 58.3 months in others. No significant differences in PFS or OS were found between (IO + CCRT/SCRT) → IO and CCRT/SCRT → IO. Pneumonitis occurred most frequently in the CCRT/SCRT → IO group. Early initiation of IO did not significantly increase irAE risk. These findings support early integration of IO with chemoradiotherapy and maintenance IO as a viable option for unresectable Stage III NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI